Glad to share and remind folks, old or new, on some of the Science backing our pipeline.
Below, more on antimicrobial / host defense peptides/proteins MOA.
Also reposting a link to my mention of the Uber ABX overview article from yesterday. One can never read it enough times IMO if one really wants to understand the true and vast potential of Brilacidin and analogs. Leveraging all the Polymedix legwork. In fact I'm thinking of framing it pg by pg :)
Anyway, I can see why Leo is excited about Brilacidin (per todays alert) as it's getting closer to the ph III launch, and perhaps with a fast-track designation (per QIDP). That likely would get us over the $2 uplist hurdle... Likely onto greener pastures.
Below is a short recap of info on a recent European presentation by RW Hancock and group out of Univ of BC. He's one the gurus in the field, presented at ECCMID 2015 as some of you might recall.
EXCERPT Professor Luca Guardabassi delivered the welcoming speech at the conference, which identified the One Health approach as vital to surmounting the global challenge of antimicrobial resistance. Afterwards, the keynote presenter, Professor Robert E.W. Hancock from the University of British Columbia, shared his fascinating research on new adjunctive approaches for treating multiple antibiotic resistant pathogen. His labstudies three basic types of research; exploring the mode of action of cationic host defense (antimicrobial) peptides and their role as modulators of innate immunity; the development of novel therapeutics based on the immunomodulatory and antibiotic activities of host defense peptides; and investigating the functional genomics of a nosocomial pathogen.
Recently, his lab developed novel anti-biofilm peptides that kill multiple species of bacteria in biofilms, work synergistically with antibiotics, and effective in animal models of biofilm infections. A recent PLOS Pathogenspaper describes the action of Broad-Spectrum Anti-biofilm Peptide in different condition. Professor Hancock mentioned that the manipulation of natural innate immunity represents a new adjunctive therapeutic strategy against antibiotic resistant infections. Cationic host defense peptides boost protective innate immunity while suppressing potentially harmful inflammation, and work synergistically with conventional therapy. His lab already examined the protection in mouse models against the superbug methicillin resistant Staphylococcus aureus (MRSA), E. coli, P. aeruginosa, MDR tuberculosis etc.
Market Data 
Markets 
AI
